Board & BedsideCLINICAL KNOWLEDGE FOR THE REAL WORLD

Microscopic Hematuria. Reading the Result and Working It Up by Risk.

Microscopic Hematuria. Reading the Result and Working It Up by Risk., Board & Bedside

Written by

in

By Daniel Borkert, FNP-C
Last reviewed November 11, 2026. Rules and figures checked against the sources named below on November 11, 2026.

Microscopic hematuria is one of the most common incidental findings in primary care. Most cases trace back to a benign cause, and a small share are the first sign of a urologic cancer. The amended AUA and SUFU guideline sorts patients into three risk tiers so the workup matches the risk, rather than sending every positive result to the same full evaluation. This guide works through that pathway, from confirming the result to closing the follow up.

In this guide

The short answer

Microscopic hematuria is 3 or more red blood cells per high power field on microscopic evaluation of a single properly collected urine specimen. A positive dipstick does not make the diagnosis. What happens next is set by risk tier rather than by reflex referral. Confirm the result on microscopy, look for infection or another nonmalignant source, place the patient in one of three tiers under the AUA and SUFU guideline as amended in 2025, and work each tier at the intensity the guideline assigns to it.

The amendment matters before anything else does. It changed management in several places, and three of the changes reach this workup directly. The age bands for women moved, a repeat urinalysis became the default action at the lowest tier, and urine cytology and markers gained one narrow role at the middle tier. Summaries written from the 2020 text, including the 2021 summary in American Family Physician, teach a workup that has since been replaced on exactly those points. The current American Family Physician summary, published in August 2026, carries the amended pathway, and this guide follows it. The American College of Physicians, in its High Value Care advice, agrees with the guideline on confirmation, on gross hematuria, and on anticoagulation, and differs on referral, where its 2016 advice predates the tier system this guide teaches. The endnotes name that difference in full.

Reading the result

Start with what the result line establishes and what it does not. The definition is a microscopy count. One properly collected specimen at 3 or more red blood cells per high power field establishes microscopic hematuria, and the older convention that asked for positive results in two of three specimens is retired. A single specimen is enough to open the question, and the panel’s reasoning was that bleeding from a cancer can be intermittent, so asking for a second positive before acting would miss findings that matter.

A dipstick is a screening flag, not a diagnosis. The guideline’s second statement directs that microhematuria not be defined by dipstick testing alone, and a dipstick reading of trace blood or greater should prompt formal microscopic evaluation. The dipstick reacts to more than intact red blood cells. Myoglobin in the urine, dehydration, recent exercise, menstrual blood, and povidone iodine can each produce a positive dipstick reading while the microscopy stays below the count that defines microhematuria. The AUA’s Choosing Wisely statement against defining microhematuria by dipstick results carries the same separation. A workup that starts from a dipstick alone is built on a result the patient may not have.

Specimen quality is part of the result. For most patients a random midstream clean catch specimen suffices, with the initial 10 mL discarded. Many squamous cells in the specimen suggest contamination, and repeat collection or catheterization should be considered so the count answers the question. Women who are menstruating should be reevaluated after menstruation ends or give a catheterized specimen. Specimens collected on the first void of the morning, immediately after prolonged recumbency, or after vigorous physical or sexual activity should not be used to assess for microhematuria. A contaminated specimen is a result that answers nothing, and the guideline writes the collection rules into the workup for that reason.

The finding itself is common and usually not cancer. Studies in the guideline’s introduction found microhematuria in 2.4 to 31.1 percent of healthy volunteers depending on the population studied, and hematuria overall accounts for more than one in five urology evaluations. The malignancy yield in microscopic hematuria populations runs about 3.1 percent in the prospective referral study of more than 3,500 patients the guideline cites, about 2.6 percent across the older screening literature, and about 1 percent in aggregate across eleven contemporary studies. Common, usually benign, and occasionally the first sign of something that cannot wait. Those three facts together are why the guideline tiers the response instead of scoping everyone or reassuring everyone.

First moves

The initial evaluation is a history, a physical examination that includes blood pressure, and a serum creatinine, with an eGFR to identify kidney disease and guide the imaging choice. The history the guideline names runs to age and sex, prior gross hematuria, irritative urinary symptoms, overall health, a detailed smoking history, family history of urologic malignancy, and genetic and exposure risk factors. It asks about menstrual and gynecologic history, infection symptoms such as fever and dysuria, flank pain suggesting stone, obstructive symptoms suggesting prostatic enlargement or stricture, and recent perineal trauma or instrumentation.

Against that history, look for the benign and nonmalignant causes. The list the guideline works from includes benign prostatic enlargement, kidney stones, urethral strictures and diverticula, trauma, recent procedures or catheterization, infection, inflammation, and gynecologic bleeding sources. When a gynecologic or nonmalignant genitourinary source is identified, the move is to evaluate and treat that source, then repeat the urinalysis after it resolves. If the microhematuria persists after resolution, or no source can be identified, the risk based evaluation begins. Where the suspected cause is a urinary tract infection, a urinalysis with microscopic evaluation follows treatment to confirm the blood is gone. It is read for red cells, not as a test of cure, and bacteriuria without urinary symptoms is common background in older adults and long term care, not a treatment trigger. That repeat keeps a treated infection from explaining a finding forever, and it belongs in the plan whenever a hematuria finding rides on one.

The repeat has a clock. The panel gives a range rather than a date, because no evidence based interval exists. Hematuria can take several weeks to a few months to resolve. Waiting at least three weeks after the cause resolves, and no more than three months, is the appropriate window. A repeat decision without a window has nothing holding it in place, and the follow up section returns to what happens to repeats nobody owns.

In long term care, the first move happens before the result exists. The ordering discipline the guidance supports is symptom driven. A urinalysis is ordered when a resident has specific urinary symptoms that point to infection, working from the Loeb criteria and the McGeer criteria, and not without a specific reason. Asymptomatic bacteriuria is common in long term care residents, so a urinalysis sent without a question behind it manufactures findings nobody asked for. The Choosing Wisely items from the infection societies advise against performing a urinalysis unless there are signs or symptoms of infection and against obtaining a urine culture without clear signs and symptoms that localize to the urinary tract, and the ACP advice in this guide’s sources advises against screening urinalysis for cancer detection in asymptomatic adults.

The three tiers and what each one gets

The workup as a decision tree

AUA guideline, amended 2025

Microscopic hematuria confirmed
3+ red cells per high power field; dipstick alone does not define it.
EXIT AT ANY POINTGross hematuria: urology referral.

Attributed to infection or another nonmalignant source?




YES
NO
Treat or resolve the cause
Repeat urinalysis with microscopy.
3 weeks to 3 months after treatment or resolution.
Blood gone?




YES
NO

RESOLVED
No workup on this finding.
Read for red cells; bacteriuria without symptoms is not a treatment trigger.




Stratify by risk tier
See tier table for bands.
SIDE EXITNephrology fork: proteinuria, dysmorphic cells or casts, declining kidney function.




Low/negligible

Repeat urinalysis within 6 months.

Intermediate

Cystoscopy and renal ultrasound.Cytology or markers only for narrow decision support.

High

Cystoscopy and CT urography.

The AUA pathway in one view. The text governs.

Risk stratification under the amended guideline runs on four inputs. The degree of hematuria on a single urinalysis, age with different bands for women and men, smoking history, and additional risk factors. A patient must meet every criterion to sit in the low/negligible tier. Meeting one or more criteria for a higher tier places the patient there. A history of gross hematuria places a patient in the high tier whatever the current count shows, and a patient who was low risk with no prior evaluation and shows 3 to 25 red blood cells per high power field on the repeat urinalysis is reclassified as intermediate.

Input Low/negligible Intermediate High
Red blood cells on one urinalysis 3 to 10 per HPF 11 to 25 per HPF More than 25 per HPF
Age in women Under 60 60 or older Never high on age alone
Age in men Under 40 40 to 59 60 or older
Smoking history Never smoked or under 10 pack years 10 to 30 pack years More than 30 pack years
Additional risk factors None One or more One or more with a high risk feature
What the tier gets Repeat urinalysis within six months Cystoscopy and renal ultrasound Cystoscopy and CT urography

The additional risk factors are irritative lower urinary tract symptoms, prior pelvic radiation, prior cyclophosphamide or ifosfamide, family history of urothelial cancer or Lynch syndrome, occupational exposures to benzene chemicals or aromatic amines in rubber, petrochemical, and dye work, and a chronic indwelling foreign body in the urinary tract. Age, male sex, smoking, the degree of hematuria, and persistence are already inside the table.

One cell of that table is the amendment’s signature change, and it is worth pausing on. Under the 2020 table, women under 50 were low risk, women 50 to 59 were intermediate, and women 60 or older were high risk on age alone. The 2025 table moves the women’s bands to under 60 and 60 or older and removes age alone as a route into the high tier for women. Any summary still printing the 2020 bands is teaching a superseded table. The cancer risk behind each tier is stated in the amendment as ranges across its validation studies, and those ranges are recorded in the endnotes rather than rounded here.

At low/negligible risk, the action is a repeat urinalysis within six months rather than cystoscopy or imaging now. This is the second 2025 change worth naming. The 2020 text framed low risk care as a shared choice between repeating the urinalysis and proceeding to cystoscopy and ultrasound. The amendment makes the repeat the default. If microhematuria persists on that repeat, the patient is reclassified as intermediate or high risk based on the repeat result and evaluated on that tier’s pathway. The low tier is a scheduled second look, not a discharge.

At intermediate risk, the workup is cystoscopy and renal ultrasound. The imaging half is ultrasound rather than CT urography by design, on the panel’s stated grounds of cost, availability, and the absence of radiation and contrast risk. This tier also carries a third change worth naming. A counseled intermediate risk patient who wants to avoid cystoscopy and accepts the risk of forgoing direct visual inspection of the bladder may be offered urine cytology or a validated urine based tumor marker to help make that decision. The arithmetic behind the offer is that intermediate pretest risk runs near 1 percent, and a negative result on a marker with a high negative predictive value brings posttest risk to about 0.1 to 0.4 percent, close to the low tier’s range. The strongest evidence the amendment cites is the STRATA randomized trial of one such marker against routine cystoscopy, with a negative predictive value of 99 percent and a 59 percent reduction in cystoscopy use on the marker based approach. Ultrasound is performed either way. A patient who forgoes cystoscopy on marker results owes a repeat urinalysis within 12 months, with cystoscopy if the microhematuria persists. Outside that one counseled decision, cytology and markers stay closed as routine tools. They should not be used routinely to decide about cystoscopy at the low or high tiers, and they should not be added routinely as adjuncts after a normal cystoscopy. One narrow preservation survives that closure. Cytology remains available for high risk patients with equivocal cystoscopy findings, and for patients with persistent microhematuria alongside irritative symptoms or carcinoma in situ risk factors after a negative workup.

At high risk, the workup is cystoscopy and axial upper tract imaging. Multiphasic CT urography, including urothelial imaging, comes first when it is not contraindicated. MR urography is the substitute when CT urography is contraindicated, and retrograde pyelography with noncontrast axial imaging or renal ultrasound serves when both are contraindicated. The bladder evaluation is white light cystoscopy. One clause overrides the tiers entirely. A family history of renal cell carcinoma, a known genetic renal tumor syndrome, or a personal or family history of or suspicious for Lynch syndrome earns upper tract imaging regardless of risk tier.

The nephrology fork

Some results change the destination rather than the intensity. Features suggesting medical renal disease are proteinuria, dysmorphic red blood cells, cellular casts, and renal insufficiency, with hypertension and a history of kidney disease in the same picture. When those features are present, the guideline directs referral for nephrologic evaluation, and the risk based urologic evaluation still proceeds alongside it. The fork is an addition, not a substitution.

The guideline names features for this fork and sets no numeric proteinuria threshold, so this guide prints none. What sends a patient toward nephrology is the pattern on the result and in the chart. Readers who want a number for the fork will have to take it from nephrology guidance, because the microhematuria guideline does not supply one, and inventing one here would misstate the source.

Special cases

Three presentations override the tier table in different directions, and each gets its handling stated separately so none of them is buried inside a referral paragraph.

Anticoagulation never explains the result away. The guideline directs the same evaluation for patients taking antiplatelet agents or anticoagulants as for patients taking neither, regardless of the type or level of therapy. The reasoning is that these drugs can unmask bleeding from an underlying lesion rather than cause bleeding from nowhere, and in a series of patients with gross hematuria on anticoagulant or aspirin therapy, tumors were found in a quarter of patients. The American College of Physicians states the same position independently.

Gross hematuria is a separate presentation. It is not a larger version of the microscopic finding. A history of gross hematuria is itself a high risk criterion in the table whatever today’s count shows. A gross presentation happening now is handled differently, on the expert consensus pathway the guideline records, with cystoscopy, upper tract imaging, and urinary cytology rather than the risk stratified workup. The American College of Physicians directs referral for all adults with gross hematuria even when the bleeding is self limited. The cancer figures behind the urgency come from studies and are stated with their sources. In the prospective referral study the guideline cites, cancer was found in 13.2 percent of gross hematuria presentations, and the ACP review puts the figure consistently above 10 percent.

Pregnancy routes to ultrasound first. The guideline’s panel discussion, written on admittedly limited data, recommends obtaining renal ultrasonography initially for microhematuria in pregnancy and considering multiphasic CT or MR urography after delivery, because few pregnant patients fall into the high risk group. That is panel guidance on thin evidence, and it is labeled as such here rather than upgraded into a rule. The guideline’s population is adults, and it does not cover children or adolescents at all, which the questions below take up.

Follow up after a negative or deferred workup

A negative risk based evaluation does not open an indefinite surveillance file. Under the amended guideline, what follows is shared decision making about whether to repeat the urinalysis in the future at all. A patient whose evaluation was negative and whose subsequent urinalysis is also negative may discontinue further evaluation for microhematuria. Persistent or recurrent microhematuria on a repeat after a negative evaluation returns to shared decision making about additional evaluation. There is no mandated surveillance duration and no annual urinalysis schedule in the amended text, and the older schedule of yearly testing after a negative workup belongs to superseded guidance. Three changes reopen a closed case. Gross hematuria, a significant increase in the degree of microhematuria, or new urologic symptoms after a negative evaluation should each start further evaluation.

The two fixed timings in this area are tier timings rather than surveillance. The low tier repeat within six months and the intermediate marker pathway repeat within 12 months are owed on their own clocks, and each needs an owner. This is the part of the pathway that fails quietly when nobody owns it. A repeat that nobody owns is a decision that decays into a lost finding, and the practice environment makes the decay easy. In practice, microscopic findings are generally read as contamination or anomaly and left unaddressed. The ACP review’s practice data measure a neighboring behavior at national scale, with surveys finding 64 percent of microscopic hematuria findings were not routinely referred for urologic evaluation. Different behavior, same direction. Findings without an owner drift.

Frequently asked questions

Does a positive dipstick mean microscopic hematuria

No. A dipstick reading of trace blood or greater is a prompt for microscopic evaluation, not the diagnosis. Microscopic hematuria is a count of 3 or more red blood cells per high power field on microscopy of a properly collected specimen, and dipstick positives have other sources, including myoglobin, dehydration, exercise, and menstrual blood.

Does a blood thinner explain the finding

No. The guideline directs the same evaluation for patients on antiplatelet agents or anticoagulants as for patients on neither. These drugs can unmask bleeding from an underlying lesion, which is the reason the finding earns the same workup rather than a smaller one.

What happens when the repeat urinalysis is still positive

It depends on which repeat it is. A benign cause treated and resolved is followed by a repeat at least three weeks after resolution and no more than three months later, and persistence after resolution starts the risk based evaluation. A low tier patient whose six month repeat still shows microhematuria is reclassified as intermediate or high risk and evaluated on that tier’s pathway. An intermediate risk patient who forwent cystoscopy on marker results and still shows microhematuria at the 12 month repeat gets cystoscopy.

Does every patient with microscopic hematuria need a CT scan

No. Imaging follows the tier. Low tier patients get a repeat urinalysis and, outside the hereditary exception, no imaging unless they are reclassified. Intermediate risk gets renal ultrasound. CT urography is the high risk study. A family history of renal cell carcinoma, a genetic renal tumor syndrome, or a history suggesting Lynch syndrome earns upper tract imaging at any tier.

What if the blood in the urine is visible

Gross hematuria is a different presentation, not a larger microscopic finding. A current gross presentation is evaluated on its own pathway, with cystoscopy, upper tract imaging, and urinary cytology, and a history of gross hematuria is separately a high tier criterion in the risk table. Referral is the move even when the bleeding stops on its own.

Does this guideline cover children

No. The AUA and SUFU guideline’s population is adults 18 and older, and it does not address children or adolescents. Persistent microscopic hematuria in a child is a different clinical question, weighted toward kidney causes rather than malignancy, and it needs pediatric guidance rather than this pathway.

Change log and corrections

First published November 11, 2026. Guideline statements and figures checked against the AUA and SUFU microhematuria guideline as amended in 2025 and the other sources below on November 11, 2026. This guide teaches the amended pathway. Material written from the 2020 text, including the 2021 American Family Physician summary, is superseded on the women’s age bands, the low tier default, and the role of urine markers.

Endnotes

Notes belonging to the table and figures above are collected here.

Tier risk ranges. The amendment’s table states the malignancy risk behind each tier as ranges across its three validation studies (Sanci et al 2021, Saxon et al 2022, Woldu et al 2021). Low/negligible runs 0 to 0.4 percent, intermediate 0.2 to 3.1 percent, and high 1.3 to 6.3 percent. The table’s own footnote records that the figures rest on the 2020 definitions of the groups. At study level, the Woldu evaluation (J Urol 2021), the largest of the three validation studies at 15,779 patients, found cancer in 0.4 percent of low, 1.0 percent of intermediate, and 2.6 percent of high risk microhematuria presentations, and the Sanci series of 1,018 patients found urinary tract malignancy in 0 percent of low, 3.1 percent of intermediate, and 5.7 percent of high risk patients by 2020 criteria. The rounded set that circulates, about 0.5 percent at low, 1 percent at intermediate, and 3 percent or more at high, matches no primary source this guide rests on and is not used.

The ACP difference. The American College of Physicians High Value Care advice of 2016 agrees with the current guideline on microscopy confirmation, on referral for gross hematuria, on evaluating patients on anticoagulant and antiplatelet therapy, and on keeping cytology and markers out of the initial evaluation. It predates risk stratification, so its referral advice turns on the absence of a demonstrable benign cause and carries no low risk off ramp. This guide presents the AUA 2025 guideline as the source for tiering and de-escalation and the ACP advice as the supporting authority for the confirmation and vigilance points, and names the difference rather than blending the two.

AAFP coverage. American Family Physician is a summary channel into family medicine, not a second signature on this guideline. Searches of AAFP’s clinical recommendations and the AFP archive for this guide found no AAFP microhematuria guideline of its own and no AAFP endorsement of this one, and AFP’s summaries carry the standing statement that coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP. The 2026 summary is cited here as the current family medicine transmission of the amended pathway.

The high risk feature. The amendment’s table phrases the high tier’s risk factor row as one or more additional risk factors with a high risk feature. This guide reproduces the table’s own terms for that row rather than expanding them, and a reader applying the tier at the chart should work from the guideline’s table directly.

The AFP reservation. The editor’s note on the 2021 summary questioned whether the routine repeat schedule earns its keep in primary care, arguing the cited evidence was thin. The validation objection in the same note has since been partly answered by the three validation studies behind the 2025 ranges. The repeat schedule skepticism has not been directly answered in the sources this guide rests on, and it is recorded here as the documented family medicine reservation about the pathway.

The marker table. The body names the STRATA randomized trial the amendment cites and quotes that trial’s and the amendment’s figures. It does not reproduce the guideline’s own table of validated urine markers and does not compare markers against each other.

Pregnancy guidance. The pregnancy handling in the special cases section is the guideline panel’s discussion on limited data, carried forward from the 2020 text without a 2025 statement. It is panel guidance, and the body labels it as such.

Sources for this page

Barocas DA, Lotan Y, Matulewicz RS, et al. Updates to Microhematuria. AUA and SUFU Guideline (2025). Journal of Urology 2025;213(5):547-557. The amended statements, the 2025 risk table as reprinted in the amendment summaries, and the follow up statements this guide teaches.

American Urological Association. Microhematuria Guideline. The guideline page and statement set for Barocas DA et al, Microhematuria. AUA and SUFU Guideline, Journal of Urology 2020;204(4):778-786, as amended in 2025. The definition, the dipstick statement, specimen collection, the benign cause repeat protocol, the anticoagulation statement, and the nephrology fork.

Azari S and Salmasi A. Microhematuria. Updated Guidelines From the American Urological Association. American Family Physician 2026;114(2):200-204. The current family medicine summary of the amended pathway, including the tier actions and the marker option for intermediate risk patients who wish to avoid cystoscopy.

Nielsen M and Qaseem A. Hematuria as a Marker of Occult Urinary Tract Cancer. Advice for High Value Care From the American College of Physicians. Annals of Internal Medicine 2016;164(7):488-497. The seven advice points, the practice data on referral, and the harm ledger this guide draws on for the follow up environment.

Colgan R, Jaffe GA, and Nicolle LE. Asymptomatic bacteriuria. American Family Physician. 2020;102(2):99-104. Its Choosing Wisely summary carries the items behind the symptom based ordering discipline in the first moves section, from IDSA, the American Geriatrics Society, SHEA, and the post acute society, and its prevalence table gives the long term care figures for bacteriuria without symptoms.

Arnold MJ. Practice Guidelines summary of the 2020 microhematuria guideline. American Family Physician 2021;104(6):655-657. Cited as the superseded summary only, for the currency note and the editor’s reservation recorded in the endnotes.

Sharp VJ, Barnes KT, and Erickson BA. Assessment of Asymptomatic Microscopic Hematuria in Adults. American Family Physician 2013;88(11):747-754. The 2012 era clinical review, cited as history. Its surveillance schedule and thresholds are superseded and appear nowhere in this guide’s recommendations.

Community listening, batch 30. Clinician teaching and discussion on allnurses, Doximity Op-Med, public clinician channels, and one family physician’s published practice reasoning, collected and graded in the research file for this article. Patterns are paraphrased and attributed by venue there, and no anecdote from those threads appears in this guide as article material.

For clinician education only — not medical advice.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *